Finn WF - Search Results

1

The phosphate binder equivalent dose.

Daugirdas JT, Finn WF, Emmett M, Chertow GM; Frequent Hemodialysis Network Trial Group. Daugirdas JT, et al. Among authors: finn wf. Semin Dial. 2011 Jan-Feb;24(1):41-9. doi: 10.1111/j.1525-139X.2011.00849.x. Semin Dial. 2011. PMID: 21338393 Review.

2

Lanthanum carbonate reduces phosphorus burden in patients with CKD stages 3 and 4: a randomized trial.

Sprague SM, Abboud H, Qiu P, Dauphin M, Zhang P, Finn W. Sprague SM, et al. Clin J Am Soc Nephrol. 2009 Jan;4(1):178-85. doi: 10.2215/CJN.02830608. Epub 2008 Dec 3. Clin J Am Soc Nephrol. 2009. PMID: 19056618 Free PMC article. Clinical Trial.

3

Cognitive function in Stage 5 chronic kidney disease patients on hemodialysis: no adverse effects of lanthanum carbonate compared with standard phosphate-binder therapy.

Altmann P, Barnett ME, Finn WF; SPD405-307 Lanthanum Carbonate Study Group. Altmann P, et al. Among authors: finn wf. Kidney Int. 2007 Feb;71(3):252-9. doi: 10.1038/sj.ki.5001932. Epub 2006 Oct 11. Kidney Int. 2007. PMID: 17035945 Free article. Clinical Trial.

4

Phosphorus management in end-stage renal disease.

Finn WF. Finn WF. Semin Dial. 2005 Jan-Feb;18(1):8-12. doi: 10.1111/j.1525-139X.2005.18116.x. Semin Dial. 2005. PMID: 15663754

5

A long-term, open-label extension study on the safety of treatment with lanthanum carbonate, a new phosphate binder, in patients receiving hemodialysis.

Finn WF, Joy MS; LAM-308 Study Group. Finn WF, et al. Curr Med Res Opin. 2005 May;21(5):657-64. doi: 10.1185/030079905X41453. Curr Med Res Opin. 2005. PMID: 15969865 Clinical Trial.

6

Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia.

Joy MS, Finn WF; LAM-302 Study Group. Joy MS, et al. Among authors: finn wf. Am J Kidney Dis. 2003 Jul;42(1):96-107. doi: 10.1016/s0272-6386(03)00554-7. Am J Kidney Dis. 2003. PMID: 12830461 Clinical Trial.

7

Lanthanum carbonate versus standard therapy for the treatment of hyperphosphatemia: safety and efficacy in chronic maintenance hemodialysis patients.

Finn WF; SPD 405-307 Lanthanum Study Group. Finn WF, et al. Clin Nephrol. 2006 Mar;65(3):191-202. doi: 10.5414/cnp65191. Clin Nephrol. 2006. PMID: 16550750 Clinical Trial.

8

Efficacy and safety of lanthanum carbonate for reduction of serum phosphorus in patients with chronic renal failure receiving hemodialysis.

Finn WF, Joy MS, Hladik G; Lanthanum Study Group. Finn WF, et al. Clin Nephrol. 2004 Sep;62(3):193-201. doi: 10.5414/cnp62193. Clin Nephrol. 2004. PMID: 15481851 Clinical Trial.

9

Urinary biomarkers: recommendations of the Joint European/United States Workshop for future research.

Finn WF, Porter GA. Finn WF, et al. Ren Fail. 1999 May-Jul;21(3-4):445-51. doi: 10.3109/08860229909085110. Ren Fail. 1999. PMID: 10416225 Review.

10

Non-contrast-enhanced computerized tomography and analgesic-related kidney disease: report of the national analgesic nephropathy study.

Henrich WL, Clark RL, Kelly JP, Buckalew VM, Fenves A, Finn WF, Shapiro JI, Kimmel PL, Eggers P, Agodoa LE, Porter GA, Shapiro S, Toto R, Anderson T, Cupples LA, Kaufman DW. Henrich WL, et al. Among authors: finn wf. J Am Soc Nephrol. 2006 May;17(5):1472-80. doi: 10.1681/ASN.2005101096. Epub 2006 Apr 12. J Am Soc Nephrol. 2006. PMID: 16611714 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results